CryoLife is a health care equipment & supplies business based in the US. CryoLife shares (CRY) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $20.25 – the same closing value as a week prior. CryoLife employs 1,200 staff and has a trailing 12-month revenue of around $287.3 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $20.25 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $18.94 |
| 200-day moving average | $23.88 |
| Wall St. target price | $32.44 |
| PE ratio | 425.7143 |
| Dividend yield | $0.03 (0.17%) |
| Earnings per share (TTM) | $0.04 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $20.25 from 2022-03-24
| 1 week (2024-10-07) | N/A |
|---|---|
| 1 month (2024-09-14) | N/A |
| 3 months (2024-07-14) | N/A |
| 6 months (2024-04-14) | N/A |
| 1 year (2023-10-14) | N/A |
|---|---|
| 2 years (2022-10-14) | N/A |
| 3 years (2021-10-18) | 20.69 |
| 5 years (2019-10-18) | 23.68 |
Valuing CryoLife stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CryoLife's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CryoLife's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 426x. In other words, CryoLife shares trade at around 426x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
CryoLife's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 181.5. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into CryoLife's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
CryoLife's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $36.8 million.
The EBITDA is a measure of a CryoLife's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $287.3 million |
|---|---|
| Operating margin TTM | 4.5% |
| Gross profit TTM | $167.8 million |
| Return on assets TTM | 1.01% |
| Return on equity TTM | 0.57% |
| Profit margin | 0.63% |
| Book value | $7.92 |
| Market Capitalization | $703.2 million |
TTM: trailing 12 months
We're not expecting CryoLife to pay a dividend over the next 12 months.
CryoLife's shares were split on a 3:2 basis on 27 December 2000. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your CryoLife shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for CryoLife shares which in turn could have impacted CryoLife's share price.
Over the last 12 months, CryoLife's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while CryoLife's is 1.5302. This would suggest that CryoLife's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.